Loading
Engineered immune cells delivered directly into the brain or spinal fluid. Some children with diffuse midline glioma, a brainstem tumour with no curative treatment, have had striking, if temporary, responses.
City of Hope IL13Rα2 CAR-T (intraventricular; one complete response 2016, phase 1 of 65 patients 2024 with 50% stable disease or better). Stanford GD2 CAR-T for H3K27M diffuse midline glioma (Majzner/Monje; Nature 2022 and 2024: radiographic and clinical improvement in most, one durable complete response). Penn EGFRvIII CAR-T showed antigen loss; dual-target CARv3-TEAM-E (MGH, 2024-26) and multi-antigen and locoregional approaches follow. Barriers: heterogeneity, antigen loss, exhaustion, neurotoxicity in a closed space.
Locoregional (intraventricular or intratumoural) delivery of CAR-T against glioma-restricted antigens, often repeated.
One cancer page and one technology page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Query for this technology: (TITLE:"CAR-T for glioma" OR ABSTRACT:"CAR-T for glioma" OR TITLE:"IL13Rα2, GD2, EGFRvIII, multi-target" OR ABSTRACT:"IL13Rα2, GD2, EGFRvIII, multi-target") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), not a curated reading list.
Shares H3 K27M (diffuse midline glioma), Armoured, logic-gated & next-gen CARs, Stanford Health Care / Stanford Cancer Institute, Neuroblastoma (paediatric).
Shares Armoured, logic-gated & next-gen CARs, Massachusetts General Hospital Cancer Center, EGFR, CAR-T cell therapy.
Shares Open the barrier so engineered immune cells can enter the brain, Blood-brain barrier (BBB), The blood-brain barrier & brain metastasis, Diffuse midline glioma, H3 K27-altered (including DIPG).
Shares City of Hope, Armoured, logic-gated & next-gen CARs, CAR-T cell therapy, Glioma & glioblastoma.
Shares H3 K27M (diffuse midline glioma), Blood-brain barrier (BBB), Diffuse midline glioma, H3 K27-altered (including DIPG), The brain: barrier and sanctuary.
Shares H3 K27M (diffuse midline glioma), Diffuse midline glioma, H3 K27-altered (including DIPG), The brain: barrier and sanctuary, Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first.
Shares EGFRvIII, The brain: barrier and sanctuary, EGFR, Glioma & glioblastoma.
Shares Neoadjuvant immunotherapy with surgical window for glioblastoma, Blood-brain barrier (BBB), The brain: barrier and sanctuary, Glioma & glioblastoma.